Mount Lucas Management’s Starling Oncology STLN Stock Holding History

Mount Lucas Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Hold	250,000	–	–	0.48%	57
2026 Q1	$768K	Hold	250,000	–	–	0.28%	107
2025 Q4	$890K	Buy	250,000 +89,500	+56%	+$332K	0.36%	93
2025 Q3	$560K	Buy	160,500 +83,500	+108%	+$286K	0.23%	136
2025 Q2	$158K	Buy	+77,000	New	+$193K	0.07%	158

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mount Lucas Management's STLN Position: Q2 2026 in Review

Mount Lucas Management held its Starling Oncology (STLN) position steady in Q2 2026 at 250,000 shares worth $1.36M. The position accounts for 0.48% of the portfolio, ranked #57.

Mount Lucas Management first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

Mount Lucas Management held 250,000 shares of Starling Oncology worth $1.36M as of Q2 2026.
Mount Lucas Management left its Starling Oncology share count unchanged in Q2 2026.
Starling Oncology made up 0.48% of Mount Lucas Management's portfolio in Q2 2026, its #57 holding.
Mount Lucas Management first reported a position in Starling Oncology in Q2 2025 and has held it in 5 quarters since.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Mount Lucas Management's 13F filing for Q2 2026, filed 10 Aug 2026.